Skin Tumor Research for Tuberous Sclerosis

Study of Skin Tumors in Tuberous Sclerosis

Recruiting Observational Study
Tuberous Sclerosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 90
Sex
Any
Study type
Observational
Participants needed
400 (estimated)
Sponsor
National Heart, Lung, and Blood Institute (NHLBI) · NIH
Who this trial is looking for

This trial is looking for adults diagnosed with tuberous sclerosis to learn more about skin tumors related to this condition. Participants will have a detailed medical history and a skin exam, and those with skin tumors may have up to eight small tissue samples taken for research.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am 18 years or older.
  • I have been diagnosed with tuberous sclerosis.

You may not be able to join if

  • I cannot give informed consent.
  • I tend to form keloids.
  • I am allergic to anesthetics.
  • I have a bleeding disorder.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Tuberous sclerosis is a rare, hereditary disease in which patients develop multiple tumors. Although not cancerous, the tumors can affect various organs, including the heart, lungs, kidneys, skin, and central nervous system, with serious medical consequences. The severity of disease varies greatly among patients, from barely detectable to fatal. This study will investigate what causes skin tumors …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
* INCLUSION CRITERIA: Patients will be those already diagnosed with TSC (definite, probable, or possible) based on clinical criteria and/or genetic testing, and ranging in age from 18 to 90 years old. The clinical features of TSC considered of major significance are: facial angiofibromas or forehe…
Contacts

Tatyana A Worthy, R.N.

(301) 827-1376

worthyt@mail.nih.gov

CONTACT

Joel Moss, M.D.

(301) 496-1597

mossj@nhlbi.nih.gov

CONTACT